 being offered EVAR or hybrid procedures. In the
setting of constrained costs and capitated care, expensive procedures for asymptomatic elderly patients with
signiﬁcant comorbidities who will not derive a meaningful survival beneﬁt are not cost-effective.

Journal of Vascular Surgery

Chaikof et al

53

Volume 67, Number 1

EVAR implants are a major component of costs of treatment. As additional devices have been introduced to the
market,